Homoharringtonine: History, current research, and future directions

Cancer

Volumn 92, Issue 6, 2001, Pages 1591-1605

  Kantarjian, Hagop M ^a   Talpaz, Moshe ^a   Santini, Valeria ^a   Murgo, Anthony ^b   Cheson, Bruce ^b   O'Brien, Susan M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Hematologic; Homoharringtonine; Leukemia; Myelodysplastic syndrome

Indexed keywords

HOMOHARRINGTONINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; LEUKEMIA; MALARIA; META ANALYSIS; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FORECASTING; HARRINGTONINES; HUMANS; LEUKEMIA; NEOPLASMS; RESEARCH;

EID: 0035883408     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U     Document Type: Article

References (103)

1. Cephalotaxine esters: Anti-leukemic advance or therapeutic failure?
2. Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China
3. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment
4. Structures of harringtonine, isoharringtonine, and homoharringtonine
5. Antitumor alkaloids from Cephalotaxus harringtonia: Structure and activity
6. Quantitative gas chromatography and gas chromatography-mass spectrometry of Cephalotaxus alkaloids
7. Quantitation of harringtonine and homoharringtonine in serum by high-performance liquid chromatography
8. Quantification of homoharringtonine and harringtonine in serum by chemical ionization mass spectrometry
9. The genus Cephalotaxus: Source of homoharringtonine and related anticancer alkaloids
10. Antitumor alkaloids
11. Harringtonine, an inhibitor of initiation of protein biosynthesis
12. Inhibition of translation in eukaryotic systems by harringtonine
13. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bone formation
14. Effect of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors
15. Influence of harringtonine on human leukemia cell differentiation
16. Induction of apoptosis by harringtonine and homoharringtonine in HL-60 cells
17. Homoharringtonine induces apoptosis in chronic myelogenous leukemia
18. Cytotoxicity and cell cycle specificity of homoharringtonine
19. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells
20. Chemical, pharmacological and clinical studies on the antitumor active principle of Cephalotaxus hainanesis Li
21. The antitumor effects and pharmacologic actions of harringtonine
22. The cytokinetic effects of harringtonine on leukemia L1210 cells. II. Studies by microscopic photometer
23. The effect of harringtonine and its allied alkaloids on the incorporation of labeled amino acids into proteins of cells of transplantable leukemias L615 and P388
24. Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemia cells sensitive and resistant to vincristine and other chemotherapeutic agents
25. Homoharringtonine - Perspectives on an active new natural product
26. Comparison of the effects of flavone acetic acid, fostriecin, homoharingtonine and tumour necrosis factor alpha on colon 38 tumours in mice
27. Effects of homoharringtonine on human neuroblastoma cell lines
28. The effects of homoharringtonine (HHT) on mouse C-1300 neuroblastoma in vitro and in vivo
29. Leukemic cell differentiation in vivo and in vitro: Arrest of proliferation parallels the differentiation induced by the antileukemic drug harringtonine
30. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro
31. Effects of homoharringtonine on protein glycosylation in human bladder carcinoma cell T-24
32. Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine
33. Modulation of drug resistance in homoharringtonine-resistant C-1300 neuroblastoma cells with cyclosporine A and dipyridamole
34. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine
35. Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines
36. Characteristics of harringtonine-resistant human leukemia HL60 cell
37. Therapeutic synergism (TS) of homoharringtonine (H) plus 5-fluorouracil (FU) against leukemia P388 (P388/o) and ARA-C-resistant P388 (P388/ARA-C)
38. Hexamethylene bisacetamide (HMBA) does not enhance the cytotoxic effects of adriamycin (AD11), 1,beta-D-arabinofuranosylcytosine (ARA-C) and harringtonine (HT) in HL-60 cells
39. Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1
40. Experimental studies on the toxicity of harringtonine and homoharringtonine
41. Pharmacokinetics of homoharringtonine in dogs
42. Clinical pharmacology of homoharringtonine
43. Central nervous system (CNS) penetration of homoharringtonine (HHT)
44. Quantitation of homoharringtonine in plasma by high-performance liquid chromatography with amperometric detection
45. Metabolism of triciribine phosphate (TCN-P), homoharringtonine (HHT), and nafidimide (BIDA) by rat hepatic microsomal enzymes
46. An analysis of 72 cases of leukemia treated with Cephalotaxus ester alkaloid
47. Clinical analysis of the therapeutic effects of semisynthetic harringtonine in treating 55 cases of nonlymphocytic leukemia
48. Treatment of acute leukemia with harringtonine, semisynthetic harringtonine or total alkaloids of Cephalotaxus hainanesis: Analysis of curative results in 46 cases
49. A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine
50. Intrathecal injection of harringtonine and homoharringtonine in treating central nervous system leukemia - Clinical analysis in 26 cases
51. Harringtonine in treatment of polycythemia vera
52. Clinical study of Cephalotaxus ester in the treatment of polycythemia vera
53. A study on the induction of differentiation of human leukemia cells by harringtonine combined with cytarabine
54. Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia
55. High remission induction (traditional SinoWestern HOAP) regimen for acute nonlymphocytic leukemia
56. Combined harringtonine or homoharringtonine chemotherapy for acute nonlymphocytic leukemia in 25 children
57. Combined HOAP and traditional Chinese medicine in treating acute non-lymphocytic leukemia
58. Clinical study of cephalotaxine ester in the treatment of acute nonlymphoid leukemia
59. Phase I clinical investigation of homoharringtonine
60. Homoharringtonine: A phase I evaluation
61. Phase I trial of homoharringtonine
62. Phase I study of homoharringtonine (NSC 141-633)
63. 3H] homoharringtonine (HHT) with the calcium antagonist receptor in the rat
64. Phase I trial of homoharringtonine administered as a 5-day continuous infusion
65. Phase I trial of homoharringtonine administered by prolonged continuous infusion
66. Phase I study of homoharringtonine (HHT) in 10 day schedule: 6 Hour infusion daily vs. continuous infusion
67. Experimental studies on the toxicity of harringtonine and homoharringtonine
68. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas
69. Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors
70. A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer
71. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer
72. A clinical trial of homoharringtonine in the treatment of advanced breast cancer
73. Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A Phase II Illinois Cancer Council Study
74. Intermittent IV homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: A phase II trial
75. Homoharringtonine: An effective new drug for remission induction in refractory nonlymphoblastic leukemia
76. Phase I/II trial of homoharringtonine in acute leukemia
77. Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study
78. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia
79. Homoharringtonine is safe and effective for patients with acute myelogeous leukemia
80. Treatment of acute myeloid leukemia with the harringtonines
81. Phase II study of homoharringtonine (HHT) for the treatment of children with refractory nonlymphoblastic leukemia (ANLL)
82. Phase I trial of homoharringtonine in children with refractory leukemia
83. Etoposide does not increase remission induction with homoharringtonine in patients with acute non-lymphoblastic leukemia
84. Homoharringtonine and amsacrine in pretreated patients with acute nonlymphocytic leukemia
85. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia
86. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia
87. Small-dose harringtonine induces complete remission in patients with acute promyelocytic leukemia
88. Acute promyelocytic leukemia: A 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage
89. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
90. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia
91. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
92. Simultaneous interferon alpha and homoharringtonine is an effective regimen in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia
93. Triple combination therapy with interferon-alpha, low-dose cytarabine and homoharringtonine in Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
94. Homoharringtonine and low-dose ara-C is a highly effective combination for the treatment of CML in chronic phase
95. The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine form a performed chiral acly moiety
96. A new series of homoharringtonine analogs exhibiting a potent antileukemic activity in vitro
97. OP5215, a new semi-synthetic homoharringtonine derivative, is highly cytotoxic on multidrug resistant cell lines
98. Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
99. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
100. A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias
101. The preparation of monoclonal antibody HI30-homoharringtonine liposomes (immunoliposomes) and targeting tests in vitro
102. Treatment of chloroquine-resistant malaria with esters of cephalotaxine: Homoharringtonine